PT3459560T - Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização dos mesmos para o tratamento de cancro - Google Patents
Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização dos mesmos para o tratamento de cancroInfo
- Publication number
- PT3459560T PT3459560T PT181889130T PT18188913T PT3459560T PT 3459560 T PT3459560 T PT 3459560T PT 181889130 T PT181889130 T PT 181889130T PT 18188913 T PT18188913 T PT 18188913T PT 3459560 T PT3459560 T PT 3459560T
- Authority
- PT
- Portugal
- Prior art keywords
- cancer
- treatment
- growth factor
- same
- factor receptor
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 102000009465 Growth Factor Receptors Human genes 0.000 title 1
- 108010009202 Growth Factor Receptors Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940116977 epidermal growth factor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161473409P | 2011-04-08 | 2011-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3459560T true PT3459560T (pt) | 2021-05-24 |
Family
ID=45888507
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT181889130T PT3459560T (pt) | 2011-04-08 | 2012-03-21 | Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização dos mesmos para o tratamento de cancro |
PT12710856T PT2694549T (pt) | 2011-04-08 | 2012-03-21 | Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização do mesmo para o tratamento de cancro |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT12710856T PT2694549T (pt) | 2011-04-08 | 2012-03-21 | Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização do mesmo para o tratamento de cancro |
Country Status (14)
Country | Link |
---|---|
US (5) | US9266960B2 (pt) |
EP (2) | EP3459560B1 (pt) |
JP (3) | JP6076963B2 (pt) |
CN (2) | CN103596981B (pt) |
AU (1) | AU2012240562B2 (pt) |
CA (1) | CA2832540C (pt) |
ES (2) | ES2872077T3 (pt) |
HK (1) | HK1243100A1 (pt) |
IL (3) | IL285335B2 (pt) |
PL (1) | PL2694549T3 (pt) |
PT (2) | PT3459560T (pt) |
SI (1) | SI2694549T1 (pt) |
TR (1) | TR201815488T4 (pt) |
WO (1) | WO2012138475A1 (pt) |
Families Citing this family (192)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2872077T3 (es) * | 2011-04-08 | 2021-11-02 | Us Health | Receptor de antígenos quiméricos anti-variante III del receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer |
CA3116051C (en) * | 2012-03-23 | 2023-09-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
EP3744736A1 (en) | 2013-02-20 | 2020-12-02 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
DK2958943T3 (da) * | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
CN111643663A (zh) | 2013-03-15 | 2020-09-11 | 细胞基因公司 | 修饰的t淋巴细胞 |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
KR20220119176A (ko) * | 2014-02-04 | 2022-08-26 | 카이트 파마 인코포레이티드 | B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법 |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
DK3129470T3 (da) | 2014-04-07 | 2021-07-05 | Novartis Ag | Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor |
GB2541599B (en) * | 2014-05-14 | 2020-05-20 | Carsgen Therapeutics Ltd | Nucleic acid for coding chimeric antigen receptor protein and T lymphocyte for expression of chimeric antigen receptor protein |
AU2015270912B9 (en) | 2014-06-02 | 2021-01-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting CD-19 |
RU2741120C2 (ru) | 2014-07-21 | 2021-01-22 | Новартис Аг | Лечение рака с использованием химерного антигенного рецептора cll-1 |
KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
KR102594343B1 (ko) | 2014-07-21 | 2023-10-26 | 노파르티스 아게 | Cd33 키메라 항원 수용체를 사용한 암의 치료 |
JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ |
BR112017001818A2 (pt) * | 2014-07-29 | 2017-11-21 | Pfizer | receptores antigênicos quiméricos específicos para egfrviii para imunoterapia de câncer |
EP3180359A1 (en) | 2014-08-14 | 2017-06-21 | Novartis AG | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
AU2015317608B2 (en) | 2014-09-17 | 2021-03-11 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
CN106973568B (zh) | 2014-10-08 | 2021-07-23 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
AU2015329444B2 (en) | 2014-10-09 | 2017-11-23 | Yamaguchi University | CAR expression vector and CAR-expressing T cells |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
AU2015361261B2 (en) * | 2014-12-08 | 2020-03-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD70 chimeric antigen receptors |
EP3240803B1 (en) | 2014-12-29 | 2021-11-24 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
AU2016212162A1 (en) | 2015-01-26 | 2017-07-13 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to CD123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
WO2016134371A2 (en) | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
CA2977434A1 (en) * | 2015-02-26 | 2016-09-01 | Var2 Pharmaceuticals Aps | Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems |
CN106146666B (zh) * | 2015-03-26 | 2019-09-06 | 科济生物医药(上海)有限公司 | 靶向cldn6的免疫效应细胞及其制备方法和应用 |
CN108367057B (zh) * | 2015-04-06 | 2022-11-22 | 赛通免疫股份有限公司 | 用于胶质母细胞瘤的egfr导向的car疗法 |
ES2876974T3 (es) | 2015-04-07 | 2021-11-15 | Novartis Ag | Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina |
KR20170134642A (ko) | 2015-04-08 | 2017-12-06 | 노파르티스 아게 | Cd20 요법, cd22 요법, 및 cd19 키메라 항원 수용체 (car) - 발현 세포와의 조합 요법 |
CN108473957A (zh) | 2015-04-17 | 2018-08-31 | 诺华股份有限公司 | 改善嵌合抗原受体表达细胞的功效和扩增的方法 |
US10738290B2 (en) | 2015-04-21 | 2020-08-11 | Novartis Ag | RNA-guided gene editing system and uses thereof |
EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
FI3298033T4 (fi) | 2015-05-18 | 2023-09-22 | Tcr2 Therapeutics Inc | Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille |
EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
DK3310805T3 (da) | 2015-06-19 | 2021-05-03 | Sebastian Kobold | Pd-1-cd28-fusionsproteiner og anvendelse deraf i medicin |
WO2017015427A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
CN108495641A (zh) | 2015-08-11 | 2018-09-04 | 塞勒克提斯公司 | 用于靶向cd38抗原和用于cd38基因失活的工程化的用于免疫疗法的细胞 |
US11098283B2 (en) | 2015-08-25 | 2021-08-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cells modified to overexpress c-Myb |
JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
JP2018526034A (ja) | 2015-09-10 | 2018-09-13 | アフィジェン・インコーポレイテッド | 腫瘍治療薬の配列決定により導かれる選択 |
EP3362569B1 (en) | 2015-10-16 | 2021-09-01 | Ludwig-Maximilians-Universität München | Cxcr6-transduced t cells for targeted tumor therapy |
WO2017070042A1 (en) | 2015-10-20 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t cell populations using akt inhibitors |
KR20180091820A (ko) * | 2015-10-23 | 2018-08-16 | 소렌토 쎄라퓨틱스, 인코포레이티드 | 프로그래밍 가능한 범용 세포 수용체 및 이의 사용 방법 |
US20180362975A1 (en) | 2015-12-04 | 2018-12-20 | Novartis Ag | Compositions and methods for immunooncology |
WO2017114497A1 (en) | 2015-12-30 | 2017-07-06 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
CN106967681B (zh) * | 2016-01-13 | 2020-06-05 | 北京马力喏生物科技有限公司 | 治疗脑胶质母细胞瘤的治疗组合物 |
CN106967684A (zh) * | 2016-01-13 | 2017-07-21 | 北京马力喏生物科技有限公司 | 共表达抗EGFRvIII嵌合抗原受体和无功能EGFR受体的转基因淋巴细胞及其用途 |
EP3405490B1 (en) | 2016-01-21 | 2021-10-20 | Pfizer Inc. | Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses |
EA201891641A1 (ru) * | 2016-01-21 | 2019-01-31 | Пфайзер Инк. | Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста |
WO2017139199A1 (en) | 2016-02-10 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible arginase |
EP3423482A1 (en) | 2016-03-04 | 2019-01-09 | Novartis AG | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
KR20220133318A (ko) | 2016-04-15 | 2022-10-04 | 노파르티스 아게 | 선택적 단백질 발현을 위한 조성물 및 방법 |
JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス,インク. | 単一ドメイン血清アルブミン結合タンパク質 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
US20210177896A1 (en) | 2016-06-02 | 2021-06-17 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
CA3026858A1 (en) | 2016-06-30 | 2018-01-04 | F. Hoffmann-La Roche Ag | Improved adoptive t-cell therapy |
CA3030837A1 (en) | 2016-07-15 | 2018-01-18 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
EP3491016A1 (en) | 2016-07-28 | 2019-06-05 | Novartis AG | Combination therapies of chimeric antigen receptors and pd-1 inhibitors |
RU2019105693A (ru) | 2016-08-01 | 2020-09-01 | Новартис Аг | Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага |
AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
CA3037882A1 (en) | 2016-09-23 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same |
AU2017341048A1 (en) | 2016-10-07 | 2019-05-23 | TCR2 Therapeutics Inc. | Compositions and methods for T-cell receptors reprogramming using fusion proteins |
US10525083B2 (en) | 2016-10-07 | 2020-01-07 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain |
CA3041284A1 (en) | 2016-10-20 | 2018-04-26 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
EP3544997A4 (en) | 2016-11-23 | 2020-07-01 | Harpoon Therapeutics, Inc. | PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN |
US20200080057A1 (en) | 2016-12-13 | 2020-03-12 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same |
WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
AU2017382902A1 (en) | 2016-12-21 | 2019-07-18 | TCR2 Therapeutics Inc. | Engineered T cells for the treatment of cancer |
AR110424A1 (es) | 2016-12-23 | 2019-03-27 | Macrogenics Inc | Moléculas de unión a adam9 y métodos de uso de las mismas |
WO2018127585A1 (en) | 2017-01-06 | 2018-07-12 | Txcell | Monospecific regulatory t cell population with cytotoxicity for b cells |
EP3346001A1 (en) | 2017-01-06 | 2018-07-11 | TXCell | Monospecific regulatory t cell population with cytotoxicity for b cells |
JP7288401B2 (ja) * | 2017-01-10 | 2023-06-07 | プレシゲン,インコーポレイテッド | 新規の遺伝子スイッチ発現系を介したポリペプチドの発現のモジュレーション |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
CN106636003B (zh) * | 2017-01-24 | 2019-07-12 | 深圳普瑞金生物药业有限公司 | 一种全人源化EGFRvIII嵌合抗原受体T细胞及其制备方法 |
EP3574005B1 (en) | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Car t細胞療法のための組成物および方法 |
US11851659B2 (en) | 2017-03-22 | 2023-12-26 | Novartis Ag | Compositions and methods for immunooncology |
CA3057505A1 (en) | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
CA3059444A1 (en) * | 2017-04-14 | 2018-10-18 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
EP3612210A4 (en) | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS |
EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
EP3621648A4 (en) | 2017-05-12 | 2021-01-20 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS MSLN AND METHOD OF USE |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
WO2018226741A1 (en) | 2017-06-05 | 2018-12-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T-cells modified to overexpress phf19 |
WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CN107338224A (zh) * | 2017-07-04 | 2017-11-10 | 成都克里斯博生物科技有限公司 | PD‑1敲除EGFRvIIICAR‑T细胞的制备 |
KR20200090151A (ko) | 2017-09-20 | 2020-07-28 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 신규한 항-hla-a2 항체 및 이의 용도 |
AU2018338192B2 (en) * | 2017-09-22 | 2022-03-03 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
US20200316122A1 (en) | 2017-10-11 | 2020-10-08 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods of producing t cell populations using p38 mapk inhibitors |
CN111630070A (zh) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
AU2018346955A1 (en) | 2017-10-13 | 2020-04-30 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
JP2021501570A (ja) | 2017-10-18 | 2021-01-21 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
CN111566124A (zh) | 2017-10-25 | 2020-08-21 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
CN108203732B (zh) * | 2017-10-27 | 2021-07-27 | 上海交通大学医学院附属仁济医院 | Trim24在胶质瘤诊断中的应用 |
US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
RU2020119365A (ru) | 2017-11-15 | 2021-12-13 | Новартис Аг | Химерный антигенный рецептор, нацеливающийся на всма, химерный антигенный рецептор, нацеливающийся на cd19, и средства комбинированной терапии |
WO2019129054A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
TW201930591A (zh) | 2018-01-08 | 2019-08-01 | 瑞士商諾華公司 | 用於與嵌合抗原受體療法併用之免疫增強rna |
CA3089051A1 (en) | 2018-01-22 | 2019-07-25 | Endocyte, Inc. | Methods of use for car t cells |
EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
CN111601825B (zh) | 2018-02-01 | 2022-11-29 | 信达生物制药(苏州)有限公司 | 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用 |
EP3749770A1 (en) | 2018-02-09 | 2020-12-16 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Tethered interleukin-15 and interleukin-21 |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
WO2019184909A1 (zh) | 2018-03-27 | 2019-10-03 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
CN110305210B (zh) | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
WO2019197678A1 (en) | 2018-04-13 | 2019-10-17 | Sangamo Therapeutics France | Chimeric antigen receptor specific for interleukin-23 receptor |
EP3784774A1 (en) | 2018-04-24 | 2021-03-03 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
CN108707199A (zh) * | 2018-05-29 | 2018-10-26 | 廊坊康宝汇泰生物技术有限公司 | 靶向tem8的嵌合抗原受体t细胞及其应用 |
CN108676098A (zh) * | 2018-05-29 | 2018-10-19 | 段海峰 | 靶向wt1的嵌合抗原受体t细胞及其应用 |
EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
BR112020025048A2 (pt) | 2018-06-13 | 2021-04-06 | Novartis Ag | Receptores de antígeno quimérico de bcma e usos dos mesmos |
EP3825404A4 (en) * | 2018-07-17 | 2022-04-13 | Noile-Immune Biotech, Inc. | CAR CONTAINING ANTI-GPC3 SINGLE STRAND ANTIBODY |
US20210292389A1 (en) | 2018-08-10 | 2021-09-23 | Sangamo Therapeutics France | New car constructs comprising tnfr2 domains |
US20210253666A1 (en) | 2018-08-30 | 2021-08-19 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
BR112021003305A2 (pt) | 2018-08-31 | 2021-05-25 | Novartis Ag | métodos para produzir células que expressam receptor de antígeno quimérico |
EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
US20220047633A1 (en) | 2018-09-28 | 2022-02-17 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
US20210347851A1 (en) | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
CN111218465A (zh) * | 2018-11-26 | 2020-06-02 | 上海恒润达生生物科技有限公司 | 一种靶向cd22的嵌合抗原受体方法及用途 |
CN113412117A (zh) | 2018-12-12 | 2021-09-17 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
TWI756621B (zh) | 2019-01-25 | 2022-03-01 | 大陸商信達生物製藥(蘇州)有限公司 | 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體 |
EP3927371A1 (en) | 2019-02-22 | 2021-12-29 | Novartis AG | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
WO2020182681A1 (en) | 2019-03-08 | 2020-09-17 | Klinikum Der Universität München | Ccr8 expressing lymphocytes for targeted tumor therapy |
WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
CA3137397A1 (en) | 2019-04-19 | 2020-10-22 | Chugai Seiyaku Kabushiki Kaisha | Chimeric receptor that recognizes engineered site in antibody |
EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
EP4023230A4 (en) | 2019-06-05 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | ANTIBODY CLEAVAGE SITE BINDING MOLECULE |
GB201909283D0 (en) | 2019-06-27 | 2019-08-14 | Cancer Research Tech Ltd | Fusion proteins with enzyme activity |
JP2022539248A (ja) | 2019-07-02 | 2022-09-07 | フレッド ハッチンソン キャンサー リサーチ センター | 組換えad35ベクター及び関連遺伝子治療改善 |
EP3769816A1 (en) | 2019-07-25 | 2021-01-27 | Ospedale Pediatrico Bambino Gesù | Car-cd123 vector and uses thereof |
WO2021019706A1 (ja) | 2019-07-31 | 2021-02-04 | 国立大学法人信州大学 | Car発現免疫細胞を含む細胞集団の製造方法 |
WO2021028359A1 (en) | 2019-08-09 | 2021-02-18 | Sangamo Therapeutics France | Controlled expression of chimeric antigen receptors in t cells |
WO2021030182A1 (en) | 2019-08-09 | 2021-02-18 | A2 Biotherapeutics, Inc. | Bifunctional single variable domain t cell receptors and uses thereof |
WO2021035170A1 (en) | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
CA3153197A1 (en) | 2019-10-03 | 2021-04-08 | Ryan T. Gill | Crispr systems with engineered dual guide nucleic acids |
EP3808766A1 (en) | 2019-10-15 | 2021-04-21 | Sangamo Therapeutics France | Chimeric antigen receptor specific for interleukin-23 receptor |
US20220389075A1 (en) | 2019-11-12 | 2022-12-08 | A2 Biotherapeutics, Inc. | Engineered t cell receptors and uses thereof |
AR120566A1 (es) | 2019-11-26 | 2022-02-23 | Novartis Ag | Receptores de antígeno quiméricos y sus usos |
IL292924A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors cd19 and cd22 and their uses |
MX2022007598A (es) | 2019-12-20 | 2022-09-23 | Instil Bio Uk Ltd | Dispositivos y métodos para el aislamiento de linfocitos infiltrantes de tumores y usos de los mismos. |
US20230141511A1 (en) | 2019-12-20 | 2023-05-11 | Ludwig Institute For Cancer Research Ltd | Car-t cell therapy targeting ngcgm3 |
JP7088902B2 (ja) * | 2019-12-27 | 2022-06-21 | クレージュ メディカル カンパニー,リミテッド | キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するtリンパ球 |
US20230111593A1 (en) | 2020-02-14 | 2023-04-13 | Novartis Ag | Method of predicting response to chimeric antigen receptor therapy |
JP2023527609A (ja) | 2020-02-21 | 2023-06-30 | ハープーン セラピューティクス,インク. | Flt3結合タンパク質および使用方法 |
BR112022017148A2 (pt) | 2020-02-27 | 2022-11-08 | Novartis Ag | Métodos para produzir células que expressam receptor de antígeno quimérico |
JP2023515211A (ja) | 2020-02-27 | 2023-04-12 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
CN115484978A (zh) | 2020-03-05 | 2022-12-16 | 尼奥克斯医疗有限公司 | 使用免疫细胞治疗癌症的方法和组合物 |
WO2021186056A1 (en) | 2020-03-20 | 2021-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Chimeric antigen receptor specific for human cd45rc and uses thereof |
CN116096861A (zh) | 2020-04-03 | 2023-05-09 | 赛立维公司 | 过继性细胞转移的增强 |
WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
CN116096862A (zh) | 2020-06-11 | 2023-05-09 | 诺华股份有限公司 | Zbtb32抑制剂及其用途 |
WO2022036068A1 (en) | 2020-08-13 | 2022-02-17 | A2 Biotherapeutics, Inc. | Gene fusions for control of genetically modified cells |
AU2021341969A1 (en) | 2020-09-08 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell phenotypes associated with response to adoptive cell therapy |
US20220090016A1 (en) | 2020-09-21 | 2022-03-24 | A2 Biotherapeutics, Inc. | Engineered immune cells with micro-clusters |
IL302700A (en) | 2020-11-13 | 2023-07-01 | Novartis Ag | Combined treatments with cells expressing chimeric antigens (vehicle) |
US20240018210A1 (en) | 2020-11-13 | 2024-01-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
GB202018554D0 (en) | 2020-11-25 | 2021-01-06 | Cancer Research Tech Ltd | Nucleic acid constructs and cells |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス,インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
CN114807042A (zh) * | 2021-01-22 | 2022-07-29 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体改造的nk细胞及其制备方法与应用 |
WO2022256448A2 (en) | 2021-06-01 | 2022-12-08 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing, or modifying genes |
TW202307210A (zh) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Cd19和cd22嵌合抗原受體及其用途 |
CA3223311A1 (en) | 2021-06-18 | 2022-12-22 | Andrea BARGHETTI | Compositions and methods for targeting, editing or modifying human genes |
AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2023021113A1 (en) | 2021-08-18 | 2023-02-23 | Julius-Maximilians-Universität Würzburg | Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs) |
TW202323521A (zh) | 2021-08-20 | 2023-06-16 | 瑞士商諾華公司 | 製備表現嵌合抗原受體的細胞之方法 |
WO2023041717A1 (en) | 2021-09-16 | 2023-03-23 | Aboleris Pharma | Anti-human cd45rc binding domains and uses thereof |
WO2023060212A1 (en) | 2021-10-06 | 2023-04-13 | Cellvie Inc. | Enhancing adoptive cell transfer by promoting a superior population of adaptive immune cells |
WO2023130040A2 (en) | 2021-12-31 | 2023-07-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell therapy with vaccination as a combination immunotherapy against cancer |
WO2023167882A1 (en) | 2022-03-01 | 2023-09-07 | Artisan Development Labs, Inc. | Composition and methods for transgene insertion |
WO2024056809A1 (en) | 2022-09-15 | 2024-03-21 | Novartis Ag | Treatment of autoimmune disorders using chimeric antigen receptor therapy |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
IN165717B (pt) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗hiv剤 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
CA2398136A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
US20060269529A1 (en) | 2002-05-07 | 2006-11-30 | Niederman Thomas M | Modified t lymphocytes and uses therefor |
CN102675462A (zh) * | 2003-06-27 | 2012-09-19 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
CA2735456C (en) * | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
WO2011041093A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
ES2872077T3 (es) * | 2011-04-08 | 2021-11-02 | Us Health | Receptor de antígenos quiméricos anti-variante III del receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer |
-
2012
- 2012-03-21 ES ES18188913T patent/ES2872077T3/es active Active
- 2012-03-21 TR TR2018/15488T patent/TR201815488T4/tr unknown
- 2012-03-21 ES ES12710856T patent/ES2696000T3/es active Active
- 2012-03-21 CN CN201280027682.4A patent/CN103596981B/zh active Active
- 2012-03-21 CN CN201710395649.1A patent/CN107188969B/zh active Active
- 2012-03-21 US US14/110,189 patent/US9266960B2/en active Active
- 2012-03-21 PL PL12710856T patent/PL2694549T3/pl unknown
- 2012-03-21 IL IL285335A patent/IL285335B2/en unknown
- 2012-03-21 SI SI201231451T patent/SI2694549T1/sl unknown
- 2012-03-21 AU AU2012240562A patent/AU2012240562B2/en active Active
- 2012-03-21 PT PT181889130T patent/PT3459560T/pt unknown
- 2012-03-21 EP EP18188913.0A patent/EP3459560B1/en active Active
- 2012-03-21 WO PCT/US2012/029861 patent/WO2012138475A1/en active Application Filing
- 2012-03-21 PT PT12710856T patent/PT2694549T/pt unknown
- 2012-03-21 JP JP2014503673A patent/JP6076963B2/ja active Active
- 2012-03-21 CA CA2832540A patent/CA2832540C/en active Active
- 2012-03-21 EP EP12710856.1A patent/EP2694549B1/en active Active
-
2013
- 2013-10-02 IL IL228686A patent/IL228686A/en active IP Right Grant
-
2016
- 2016-01-13 US US14/994,403 patent/US9624306B2/en active Active
- 2016-10-06 JP JP2016198519A patent/JP2017060475A/ja active Pending
-
2017
- 2017-03-03 US US15/448,707 patent/US10570214B2/en active Active
- 2017-08-29 IL IL254201A patent/IL254201B/en unknown
-
2018
- 2018-02-22 HK HK18102573.1A patent/HK1243100A1/zh unknown
- 2018-07-20 JP JP2018137193A patent/JP6748157B2/ja active Active
-
2020
- 2020-01-24 US US16/751,643 patent/US11124580B2/en active Active
-
2021
- 2021-08-24 US US17/410,129 patent/US11879017B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285335A (en) | Chimeric antigen receptors against epidermal growth factor receptor variant iii and their use in cancer therapy | |
IL250691A0 (en) | Anti-ox40 antibodies and methods of using them | |
HK1205144A1 (en) | Bispecific chimeric antigen receptors and therapeutic uses thereof | |
HK1245840A1 (zh) | 使用嵌合細胞因子受體逆轉腫瘤微環境的影響 | |
HK1226081A1 (zh) | 修飾的抗表皮生長因子受體抗體及其使用方法 | |
ZA201308022B (en) | Anti-cd40 antibodies and methods of use | |
EP2748199A4 (en) | ANTI-OX40 ANTIBODIES AND METHOD FOR THEIR USE | |
ZA201306451B (en) | Anti-il-6 receptor antibodies and methods of use | |
GB201114858D0 (en) | Anti-nerve growth factor antibodies and methods of using the same | |
GB2504887B (en) | Anti-Nerve growth factor antibodies and methods of preparing and using the same | |
GB201517547D0 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
PL3020730T3 (pl) | Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych | |
GB2504888B (en) | Anti-Nerve growth factor antibodies and methods of preparing and using the same | |
EP2614084A4 (en) | HUMANE FOLAT RECEPTOR BETA ANTIBODIES AND METHOD FOR THEIR USE | |
HK1190094A1 (zh) | 用於治療前列腺癌的抗-α- 整聯蛋白抗體 | |
IL229764A0 (en) | Antibodies against human epo receptor and methods of their use | |
EP2832363A4 (en) | EPIDERMALLY GROWTH FACTOR RECEPTOR SURFACE ANTIGEN EPITOPES AND USE THEREOF | |
HUS2200012I1 (hu) | Idegi növekedési faktor elleni ellenanyagok és eljárások elõállításukra és alkalmazásukra | |
GB201519606D0 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
GB2505352B (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same |